Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...

The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, an institute of national importance, has developed a nickel-titanium alloy based occlusion device ...

Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...

Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...

Patients being treated with dual-antiplatelet therapy (DAPT) consisting of clopidogrel plus aspirin following atrial septal defect (ASD) closure can safely discontinue clopidogrel after 3 months ...